Theme:

Urologic Oncology 2017
Past Report of Prostate Cancer-2015

Urologic Oncology 2017

Conference Series LLC invites all the participants from all over the world to attend ‘3rd International Conference on Urologic Oncology’ to be held during June 26, 2017 at Baltimore, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. 

Urologic Oncology 2017 is a global platform to discuss and learn about Urologic Oncology: Current Topics and Future Perspectives, Urologic Cancer and Its Complications, Urologic Cancer and Treatment, Living and Managing Urologic Cancer, Urologic Oncology in Market, Clinical Case Study, Urologic Cancer and Alternative Medicine, Latest Research on Urologic Oncology, Technological Tools in Urologic Oncology and Emerging focus in Urologic Oncology Research. The Urologic Oncology World Congress 2017 is the world’s largest multidisciplinary Urologic cancer meeting. Urologic cancer conferences include scientific keynote lectures, symposia, workshops, exhibitions with the support from Oncology Society and American Oncology Society. Cancer conferences include European oncology conferencessurgical oncology global cancer conference and cancer conferences

Conference Series LLC, the host of this conference is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe

Track 1 - Urologic Oncology

Urologic Oncology is the study of urologic cancer.Urologic Cancer is an abnormal and uncontrolled growth of cells found in your prostate gland, bladder or kidney, as well as testicular in both men and women. Causes of Urologic Oncology include age, genetics, diet, medication, obesity and sexually transmitted diseases. Almost all Urologic Cancers are adenocarcinomas. Interventional oncology procedures provide minimally invasive, targeted treatment of Urologic Cancer. Urologic Cancer often has no early symptoms. Advanced Urologic Cancer can cause men to urinate more often or have a weaker flow of urine, but these symptoms can also be caused by benign prostate conditions. Molecular Oncology of Urologic Oncology emphasizes the genes, proteins and biologic pathways that are being evaluated today and will be tested in the future to derive the molecular signature of each newly diagnosed Urologic Oncology. Cellular Oncology involves in basic and translational cancer research on the cell and tissue engineering of prostate. Urologic Cancer usually grows very slowly. Most men with Urologic Cancer are older than 65 years and do not die from the disease. Finding and treating Urologic Cancer before symptoms occur may not improve health or help you live longer. 

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Urologic Oncology Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Urologic Oncology Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Urologic Oncology Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Urologic Oncology Update, January 24-27, 2017 Colorado, USA.

Track 2 - Urologic Cancer and Its Complications

Urologic Cancer can cause a number of complications from local and distant spread which include blockage of the bladder by urethral obstruction, bleeding in the urine, blockage of the tubes draining the kidneys into the bladder (ureters), pelvic pain, bony pain, tiredness and death. Urologic Cancer most commonly spreads to lymph node which is known as Lymph node cancer. Long-term complications which can arise following surgery include Impotence, Incontinence, Obstruction and disease recurrence. Cancers of the prostate can spread to esophagus which is known as Esophageal cancer. However, the lack of testosterone can lead to a number of side effects which include Osteoporosis, Diabetes, Cardiovascular disease and Weight gain. A recent large study showed an increased risk of pancreas cancer in people with a father, brother or son diagnosed with Urologic Cancer.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 3 - Prostatitis

Prostatitis is a frequently painful condition that involves inflammation of the prostate and sometimes the areas around the prostate. Types of Prostatitis include acute bacterial prostatitis (ABP), chronic bacterial prostatitis (CBP), nonbacterial prostatitis and prostatodynia and may cause infectious diseases. Causes and Symptoms of Prostatitis include: urinary tract infection, recent bladder infection, enlarged prostate and symptoms-frequent urge to urinate, difficulty urinating, pain or burning during urination, chills and fever. The treatment for prostatitis depends on the underlying cause and type of prostatitis. Treatment modalities may include the following: Antibiotics, Anti-inflammatory medications, Alpha-blockers, Lifestyle changes and Acupuncture. Prevention of prostatitis includes practice good hygiene and keeps your penis clean, drink enough fluids to cause regular urination and early treatment of a possible urinary tract infection.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track-4 Prostatic Calcification

Prostatic calcification is a common finding, especially after the age of 50. They may be solitary but usually occur in clusters. Interventional oncology procedures provide minimally invasive, targeted treatment of Urologic Oncology and can also be treated by using cancer therapy. Variable appearance from fine granules to irregular lumps and can range in size from 1 to 40mm. If there is significant prostatic hypertrophy the calcifications can project well above the pubic symphysis. Prostatic calcification is most often an incidental; asymptomatic finding but it can cause symptoms such as dysuria, infection, haemautira, obstruction or Chronic Pelvic Pain and can be detected by using cancer biomarkers.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Urologic Oncology Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Urologic Oncology Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Urologic Oncology Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Urologic Oncology Update, January 24-27, 2017 Colorado, USA.

Track-5 Prostate Staging

Prostate Staging is a way of describing where the cancer is located, if or where it has spread, and whether it is affecting other parts of the body. Doctors use cancer diagnostic methods to find out the cancer's stage, so staging may not be complete until all of the tests are finished. Staging for Urologic Oncology also involves looking at test results to find out if the cancer has spread from the prostate to other parts of the body. Knowing the stage helps the doctor to decide what kind of treatment is best and can help predict a patient's prognosis, which is the chance of recovery. There are different stage descriptions for different types of cancer. The Urologic Oncology World Congress 2016 is the world’s largest multidisciplinary prostate cancer meeting.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track-6 Screening for Urologic Cancer

Tests commonly used to screen for Urologic Cancer include PSA screening - Prostate specific antigen (PSA) test measures the level of PSA in the blood. PSA is a substance made by the prostate. The levels of PSA in the blood can be higher in men who have Urologic Oncology. The main type of surgery for Prostate Cancer is known as a radical prostatectomy. In this operation, the surgeon removes the entire prostate gland plus some of the tissue around it, including the seminal vesicles. The Prostascint scan was developed in order to help doctors detect the spread of Prostate Cancer to other parts of the body, particularly the lymph node cancer. Clinical case discussions on Urologic Cancer include Case Reports on Urologic Cancer, Case Study: Castrate-Resistant Prostate Cancer. Proton therapy for Urologic Cancer is a treatment option that involves using a focused ray of proton particles to destroy cancerous tissues. The cancer diagnosis and screening segment is expected to total $12.1 billion in 2012 and $17.4 billion in2017, a CAGR of 7.5%.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA

Track-7 Prostate Surgery

Radical prostatectomy is an operation to remove the prostate gland and some of the tissue around it. It is done to remove Urologic Oncology. This operation may be done by open surgery or it may be done by laparoscopic surgery. In open surgery, the surgeon makes an incision to reach the prostate gland. Cancer Sciences is a study of cancer cells that causes tumor and technically the therapy is processed. Curative treatment options include Cancer therapies such as radical prostatectomy (RP), external beam radiotherapy and brachytherapy. Active surveillance is a strategy of close monitoring, typically using serum PSA, repeat prostate biopsies and/or MRI, keeping curative treatment in reserve for those with early evidence of disease progression. Anti-cancer drugs are also called anti-neoplastic agents or chemotherapeutic agents which are used to treat Urologic Oncology.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Urologic Oncology Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Urologic Oncology Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Urologic Oncology Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Urologic Oncology Update, January 24-27, 2017 Colorado, USA.

Track 8 - Radical Prostatectomy

For laparoscopic surgery, the surgeon makes several small incisions in the belly. Robotic-assisted laparoscopic radical prostatectomy is surgery done through small incisions in the belly with robotic arms that translate the surgeon's hand motions into finer and more precise action. Risks after surgery are Problems controlling bowel movements, Problems controlling urine, Erectile Dysfunction, Injury to the rectum, Urethral stricture. As a segment, surgical and radiation therapy should total $9 billion in 2012 and nearly $14.3 billion in 2017, a CAGR of 9.7%.A prosthesis is a device designed to replace a missing part of the body or to make a part of the body work better. Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 9 - Diagnosis of Urologic Cancer

Early Urologic Cancers and Prostate Cancer usually don’t cause symptoms, but more advanced cancers are sometimes first found because of symptoms they cause. Whether cancer is suspected based on cancer diagnosis tests or symptoms, the actual diagnosis can only be made with a prostate biopsy. TRUS is often used to look at the prostate when a man has a high PSA level or has an abnormal DRE result. It is also used during a prostate biopsy to guide the needles into the right area of the prostate. Pathologists grade Urologic Cancer and Prostate Cancer according to the Gleason system. This system assigns a Gleason grade, using numbers from 1 to 5 based on how many cells in the cancerous tissue look like normal prostate tissue and can be treated using radiation therapy.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track 10 - Urologic Cancer Treatment

There are many treatment options for Urologic Cancer and Prostate Cancer that is confined to the prostate gland. Historical standard options include Radical prostatectomy, External beam therapy and Active surveillance. Cancer that leads to bone metastasis and survival for bone cancers has improved in recent years by Bone marrow Cancer Survival. The newer options avoid or minimize some of the unpleasant side effects sometimes associated with the standard therapies. Bone cancer stages are important for the treatment of cancer. It can be treated using Bone Marrow Transplantation. These options include nerve-sparing radical prostatectomy, conformal external beam radiation therapy, image-guided radiation therapy, proton beam therapy and brachytherapy. Sarccoma cancer of prostate occurs in relatively younger men between the ages of 35 and 60.A digital rectal examination will be done to assess the prostate gland. A blood test will be performed to measure your PSA level and to assess your response to the blood cancer treatment. An elevated level of PSA can indicate the presence of Urologic Oncology.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Urologic Oncology Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Urologic Oncology Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Urologic Oncology Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Urologic Oncology Update, January 24-27, 2017 Colorado, USA.

Track 11 - Treating Advanced Urologic Cancer

Treatments that slow the spread of advanced Urologic Cancer and relieve symptoms often cause side effects. Some patients, often those who are older, decide that the risk of side effects outweighs the benefits of treatment. These patients may choose not to treat their advanced Urologic CancerEndocrine therapy may reduce tumor size and levels of prostate specific antigen (PSA) in most men. Provenge is an immune therapy created by harvesting immune system or immune cells from a patient, genetically engineering them to fight Urologic Oncology, and then infusing them back into the patient.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 12 - Urologic Cancer and Alternative Medicine

Urologic Cancer patients undergoing conventional therapies also can benefit from nutritional supplements and herbal support. Nutrition plays a very important role in cancer treatment. Prostate Oncology analytics provides evidence-based care, utilizes a counseling model within traditional preauthorization management for chemotherapeutic drugs, symptom-management drugs and supporting agents. Scientific evidence shows that nutrition and physical activity are the two most important modifiable risk factors to alter the course of cancer, prevent its occurrence, and stop its progression. Prostate oncologic emergency may be defined as any acute potentially morbid or life-threatening event directly or indirectly related to a patient's tumor or its treatment. Supplements are intended to provide nutritional support. Herbal medicines rarely have significant side effects when used appropriately and at suggested doses. Some types of cancers rarely spread to the brain, such as colon cancer or Urologic Cancer. Brain tumor treatment can be done by Radiation, Surgery and Chemotherapy which depends on the size and type of the tumor. Measures may be taken, starting 2 weeks before surgery, to prevent surgical complications, reduce pain and swelling, speed healing, support the immune system, and reduce or prevent the spread of cancer cells. Measures may be taken, continuing for 4 weeks after surgery, to prevent surgical complications, reduce pain and swelling, speed healing, support the immune system, and reduce or prevent the spread of cancer cells. 

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track 13 - Latest Research on Urologic Oncology

Scientists continue to look at new ways to prevent, treat, and diagnose Urologic Cancer. Although the specific underlying mechanisms of prostate carcinogenesis remain unknown, Urologic Cancer is thought to result from a combination of genetic and environmental factors altering key cellular processes. Research has already led to a number of advances in these areas. Some researchers think that diet may affect a man's chances of developing Urologic Cancer. Active mitochondrial mutagenesis in Urologic Cancer suggests a prominent role of increased cellular oxidative stress in neoplastic transformation and the increased susceptibility of neoplastic cells to oxidative damage. Some research suggests that high levels of testosterone may increase a man's risk of Prostate Cancer. As in the normal prostate, the initial stages of Prostate Cancer progression depend on androgens that increase proliferation and inhibit apoptosis. Researchers are studying changes in genes that may increase the risk for developing Urologic Cancer. Several studies have explored ways to prevent Urologic Cancer. Scientists are also looking at ways to stop Urologic Cancer from returning in men and women who have already been treated for the disease. Some researchers are working to develop new blood tests to detect the antibodies that the immune system produces to fight Urologic Cancer. 

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Urologic Oncology Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Urologic Oncology Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Urologic Oncology Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Urologic Oncology Update, January 24-27, 2017 Colorado, USA.

Track 14 - Technological Tools in Urologic Oncology

New technology is offering hope that men and women could one day avoid having to undergo an invasive procedure to determine whether they might have Urologic Cancer. Pomegranate fruit extracts possess polyphenol and other compounds with ant proliferative and anti-inflammatory effects in prostate. Feeding of pomegranate fruit extract to mice affords substantial protection from the adverse effects of UVB radiation via modulation in early biomarkers of photo carcinogenesis. Biological molecules that provide a clear indication of disease also known as biomarkers are used for molecular tests to diagnose Urologic Cancer. If patients with multiple lymphomatous polyposis of the gastro intestinal tract have obstructive urinary symptoms, involvement of the prostate gland by lymphoma should be considered, and appropriate diagnostic studies should be performed. The majority of Urologic Cancer deaths result from metastatic disease, which tends to initially respond to well to chemotherapeutic agents that cause DNA damage. New biomarkers are allowing more precisely detecting Urologic Cancer, guiding decisions about the therapies we use to treat, monitoring response to treatment and track the progression of cancer.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 15 - Urologic Oncology in Market

Growth in the overall urological device market will be driven by improved diagnosis rates, particularly for Urologic Cancer and benign prostatic hyperplasia. Comparative oncology is the study of Urologic Cancer that naturally occurs in animals and the comparison to its human counterpart in order to identify treatments and cures that can benefit both humans and animals. Radio Oncology or radiotherapy is therapy using ionizing radiation, generally as part of Urologic Cancer treatment to control or kill malignant cells. External beam radiation therapy is currently the most frequently used primary treatment method for Urologic Cancer, but it is predicted to be overtaken by robotic prostatectomy surgery by 2013. Other treatments include brachytherapy, cryotherapy and high-intensity focused ultrasound (HIFU), with the developing market for HIFU estimated to grow at a compound annual growth rate (CAGR) of 91% by 2016.Clinical Oncology encompasses the nonsurgical aspects of cancer care, including therapeutic administration of ionizing radiation and cytotoxic chemotherapy.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track 16- PCa Oncology and Clinical Trials

Clinical scientists and laboratory investigators study the basic biology of Urologic Oncology to hunt for even better ways to detect it and treat it. Preclinical trials for metastatic Urologic Oncology and Clinical trials for advanced Urologic Oncology play a crucial role in moving new treatments to patients. New treatments on Urologic Oncology include Surgery, Radiation, Hormonal Therapy, Chemo therapy, Biologic therapy and Bisphosphonate therapy. Unlike vaccines against infections like measles or mumps, Urologic Oncology vaccines are designed to help treat, not prevent, Urologic Oncology. One possible advantage of these types of treatments is that they seem to have very limited side effects. Drug therapeutics is expected to reach $8.1 billion in 2012 and nearly $18.6 billion in 2017, a CAGR of 18%.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Urologic Oncology Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Urologic Oncology Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Urologic Oncology Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Urologic Oncology Update, January 24-27, 2017 Colorado, USA.

Track 17 - State-of-the art: vision on the future

Current state of the art, multimodality research and future visions for the treatment of patients with Urologic Cancer: consensus results from challenges and chances in Urologic Cancer research .A urologist, a radiation oncologist, and a medical oncologist will give you the most comprehensive assessment of the available treatments and expected outcomes. Nuclear scans make pictures based on the body’s chemistry rather than on physical shapes and forms PET/CT scanners give information on any areas of increased cell activity. Urologic Cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. Taken together, the prostate biopsy scenario is currently becoming distinctively complex. It has clearly moved far beyond any Urologic Cancer detection, or avoiding biopsy-related complications such as infections or patients’ anxiety. Importantly, the future of prostate imaging especially of multiparametric MRI-based technology has already begun.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 18- Oncologists: Urologic Oncology

An oncologist is a doctor who specializes in treating people with cancer. The oncologist’s research into the causes, prevention, detection, and treatment of prostate is going on in many medical centers throughout the world. The Urologic Oncology World Congress 2017 is the world’s largest multidisciplinary Urologic Oncology meeting. Understanding the mechanisms of prostate cancer initiation and progression should have a significant impact on development of novel therapeutic approaches that can help to combat the disease. New research on gene changes linked to Urologic Cancer is helping scientists better understand how Urologic Oncology develops. Ductal adenocarcinoma often involves the central ducts of the gland and may present as an exophytic papillary lesion in the prostatic urethra. The tumour presents in elderly men with haematuria or obstructive symptoms. For this reason, they are often seen in Transurethral Resection (TUR) specimens and at Radical Prostatectomy (RP), and are less often found in needle biopsies. Researchers continue to look for foods (or substances in them) that can help lower Urologic Cancer risk. The diabetes drugs will reduce glucose uptake, disrupt glycolysis, and reduce tumor growth without significant side effects in both adenocarcinoma pancreas and prostate. Doctors agree that the prostate-specific antigen (PSA) blood test is not a perfect test for finding prostate cancer early. It misses some cancers, and in other cases it is elevated when cancer isn’t present. Researchers are working on two strategies to address this problem. Newer treatments are being developed, and improvements are being made among many standard Urologic Cancer treatment methods. Several other types of vaccines to treat Urologic Cancer are being tested in clinical trials. One example is PROSTVAC, which uses a virus that has been genetically modified to contain prostate-specific antigen (PSA).

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track 19 – Urologic Oncology Case Reports 

Urologic Oncology case reports play a crucial role in moving new treatments to patients who need those most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Oncology Esthetics is the practice of safe and beneficial spa services by individuals trained to understand how Urologic Oncology and associated medical treatments affect the body. Prostate Oncology Nutrition includes the current therapies used to treat pediatrics health and nutrition related side effects. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients. If a patient with prostate carcinoma develops metastatic disease of musculoskeletal oncolgy, the bone lesion may become dense and hard. There are currently more than several Phase III drug trials and more than 90 Phase I/II trials in process for Urologic Oncology in North America and Europe.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Urologic Oncology Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Urologic Oncology Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Urologic Oncology Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Urologic Oncology Update, January 24-27, 2017 Colorado, USA.

Track 20 – Entrepreneur Investments Meet

A key ingredient in successful entrepreneurship is self-knowledge. Urologic Oncology-2016 aims to bring together all existing and budding bio entrepreneurs to share experiences and present new innovations and challenges in cancer community. Each year, over a million companies are started in the world with about 5–10 of them classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creation. This gestalt in the entrepreneur's perception of the relationship between the invention and final product is refined into a business model that describes how the venture will make money or provide an appropriate return to the potential investors. Cancer science is complex and rapidly changing and requires a specialized knowledge to understand the value of the innovation and its competitive position in the industry. This three day community-wide conference will be a highly interactive forum that will bring experts in areas ranging from Urologic Oncology to signalling pathways to novel therapeutic approaches to the scientific hub. In addition to our outstanding speakers, we will also showcase short talks and poster presentations from submitted abstracts .The speakers will discuss state-of-the-art treatments, current guidelines, clinical challenges, and review recent trial data and emerging therapeutic approaches with the potential to impact clinical practice. This session will include combined efforts of World-renowned speakers, the most recent techniques, developments, and the newest updates in Urologic Oncology.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

 

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date June 26-28, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Conferenceseries Destinations